Table 1 |
|||
|
Background data for patients with rheumatoid arthritis (RA) |
|||
|
Bisphosphonate group (n = 42) |
Bisphosphonate + statin group (n = 35) |
P-value (Student's t-test) |
|
|
|
|||
|
Age, years |
66.4 ± 6.2 (49.3, 77.6) |
65.3 ± 6.8 (52, 76.8) |
0.463 |
|
Sex |
|||
|
Male |
2 |
0 |
|
|
Female |
40 |
35 |
|
|
59 > |
3 |
8 |
|
|
60-69 |
24 |
17 |
|
|
70 < |
13 |
10 |
|
|
Disease duration, years |
24.9 ± 10.6 (6.1, 54.3) |
20.8 ± 8.9 (5.9, 38.) |
0.083 |
|
Bisphosphonates |
|||
|
Alendronate |
31 |
26 |
|
|
Etidronate |
4 |
5 |
|
|
Risedronate |
7 |
4 |
|
|
Administered |
|||
|
> 4 years |
29 |
22 |
|
|
1 to 4 years |
13 |
13 |
|
|
Prednisolone, mg |
2.4 ± 2.0 (0, 6.0) |
2.8 ± 2.1 (0, 7.0) |
0.355 |
|
+ |
30 |
28 |
|
|
- |
12 |
7 |
|
|
Methotrexate, mg |
5.2 ± 3.2 (0, 10) |
4.1 ± 3.1 (0, 10) |
0.140 |
|
+ |
34 |
25 |
|
|
- |
8 |
10 |
|
|
Vitamin D3, μg |
0.5 |
0.5 |
|
|
+ |
7 |
3 |
|
|
- |
35 |
32 |
|
|
|
|||
|
Results are presented as mean ± SD (range) or number of patients. P-values are for comparisons between the two treatment groups. |
|||
|
Nagashima et al. Arthritis Research & Therapy 2012 14:R224 doi:10.1186/ar4063 |
|||
